Pharma BD Deal Intelligence
FierceBiotech reported the deal as immediately accretive to 2010 EPS via royalty elimination and tax attributes, with Endo raising guidance to $3.30-$3.35 —…
Penwest Pharmaceuticals agreed to be acquired by Endo for $5.00 per share in cash, with Endo being Penwest's long-time partner in the development and…
Zacks maintained a neutral long-term stance (#3 Hold) on Endo following the back-to-back Penwest and Qualitest deals, citing solid OPANA economics offset by…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Endo agreed to acquire Penwest at $5.00/share cash, ~$144M enterprise value. Eliminates royalty stream on OPANA ER. Closed November 4, 2010.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co. (this deal) | 2010 | $144M | 13 |
| Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation | 2000 | $250M | 34 |
| Endo Pharmaceuticals Inc. / Indevus Pharmaceuticals, Inc. | 2009 | $370M | 33 |
| Endo Pharmaceuticals Inc. / SkyePharma plc | 2003 | $120M | 17 |
| Endo Pharmaceuticals Inc. / HealthTronics, Inc. | 2010 | $223M | 17 |
| Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals | 2010 | $1.2B | 17 |
| Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc. | 2011 | $2.9B | 13 |
← Browse all deals · How we score deals
More: 2010 deals · Endo Pharmaceuticals Inc. deals · Other deals